It was a delight to be able to discuss with Martin Metz (Charité – Universitätsmedizin Berlin, Berlin, Germany) the results of the 52-week extension study (NCT02649218), which investigated the monoclonal anti-IgE antibody, ligelizumab, in patients who had not achieved complete urticaria activity control with omalizumab.
His abstract entitled ‘Efficacy of ligelizumab in chronic spontaneous urticaria patients previously inadequately controlled with omalizumab; analysis of the Phase 2 program’ was presented at the EADV Virtual Congress, 29-31 October 2020.
- What are the limitations of the current standard of care for chronic spontaneous urticaria? (0:16)
- What is the rationale for the use of ocrelizumab in chronic spontaneous urticaria patients previously inadequately controlled with H1-antihistamines? (0:40)
- Could give us a brief overview of the 2019 Phase II study and its findings? (1:26)
- What have we learned from your recent analyses of this study’s data in terms of possible predictors of response to ligelizumab? (2:18)
- What are the implications of these findings and what further study is needed? (3:06)
Disclosures: Martin Metz was an investigator of this phase II study and has acted as a speaker/ consultant for Novartis.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of EADV Virtual Congress 2020
Share this Video
Related Videos In Dermatological Conditions
Jonathan Bernstein, AAAAI 2021: Final results from the HELP Study
touchIMMUNOLOGY caught up with Jonathan Bernstein (University of Cincinnati; Bernstein Allergy Group, Bernstein Clinical Research Center, Cincinnati, OH, USA) to discuss the findings from the HELP study, investigating lanadelumab for the prevention of hereditary angioedema (HAE) attacks. The abstract ‘Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Use of Long-Term Prophylaxis: Final […]
Jonathan Bernstein, AAAAI 2021: Hereditary Angioedema – Prevalence, Pathogenesis, and Treatment Options
touchIMMUNOLOGY caught up with Jonathan Bernstein (University of Cincinnati; Bernstein Allergy Group, Bernstein Clinical Research Center, Cincinnati, OH, USA) to discuss the prevalence of hereditary angioedema, lanadelumab as a treatment option, and the current challenges faced by patients. The abstract ‘Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Use of Long-Term Prophylaxis: […]
Su Lwin: Epidermolysis Bullosa and Gene Therapy (Part 2)
It was lovely to speak to our Expert Faculty member, Su Lwin (King’s College London, London, UK), about the development and clinical application of gene and cell therapy for individuals with epidermolysis bullosa. Questions Could you tell us a little about your research into spray-on gene therapy for recessive dystrophic epidermolysis bullosa? (0:18) Could you […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!